Metabolic dysfunction-associated steatotic liver disease (MASLD), is the most common form of chronic liver disease worldwide.

Drugs made to treat diabetes and weight loss could stop or even reverse a severe liver disease, according to a new study. The ...

Cedars-Sinai investigators have discovered a signaling interaction between two proteins in cells that controls fat ...

How a commonly “silent disease” is driving urgency and novelty in the liver disease treatment paradigm and what can we hope for.

Key outcomes of all-cause mortality and portal hypertension complications are improved with SGLT2inhibitors, new research ...

Too Much Chicken? New Research Finds Link to Increased Risk of Early DeathA recent study published in the journal Nutrients ...

Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo.

Zurich (Switzerland), May 5, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today ...

Semaglutide, a GLP-1 receptor agonist sold under brand names Wegovy and Ozempic, is approved for weight loss and blood sugar ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...